Thyroid, porcine

Identification

Name
Thyroid, porcine
Accession Number
DB09100
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Hormones
Description

Desiccated thyroid or thyroid extract, refers to porcine or bovine thyroid glands, dried and powdered for therapeutic use. In the last few decades, pork alone is the usual source. Desiccated (dried) thyroid is a combination of hormones that are normally produced by your thyroid gland to regulate the body's energy and metabolism. Desiccated thyroid is given when the thyroid does not produce enough of this hormone on its own. Desiccated thyroid treats hypothyroidism (low thyroid hormone). It is also used to treat or prevent goiter (enlarged thyroid gland), and is also given as part of a medical tests for thyroid disorders. This medicine should not be used to treat obesity or weight problems.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Pig thyroid
  • Porcine thyroid
  • Sus scrofa thyroid
  • Thyroid (pork)
  • Thyroid extract, porcine
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thyroid Tab 125mgTablet125 mgOralErfa Canada 2012 Inc1951-12-31Not applicableCanada
Thyroid Tab 30mgTablet30 mgOralErfa Canada 2012 Inc1951-12-31Not applicableCanada
Thyroid Tab 60mgTablet60 mgOralErfa Canada 2012 Inc1951-12-31Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Armour ThyroidThyroid, porcine (30 mg/1)TabletOralAllergan1996-04-01Not applicableUs
Armour ThyroidThyroid, porcine (120 mg/1)TabletOralA-S Medication Solutions1996-04-012016-04-30Us
Armour ThyroidThyroid, porcine (15 mg/1)TabletOralPhysicians Total Care, Inc.2004-01-152011-06-30Us
Armour ThyroidThyroid, porcine (60 mg/1)TabletOralA-S Medication Solutions1996-04-01Not applicableUs50090 019020180913 8702 1giao4z
Armour ThyroidThyroid, porcine (60 mg/1)TabletOralA S Medication Solutions1996-04-01Not applicableUs00456 0459 01 nlmimage10 760ebb35
Armour ThyroidThyroid, porcine (120 mg/1)TabletOralAllergan1996-04-01Not applicableUs0456 046120180913 8702 s8ysxu
Armour ThyroidThyroid, porcine (120 mg/1)TabletOralPhysicians Total Care, Inc.2004-12-062011-06-30Us
Armour ThyroidThyroid, porcine (90 mg/1)TabletOralA-S Medication Solutions1996-04-01Not applicableUs50090 169220180913 8702 42s5m0
Armour ThyroidThyroid, porcine (15 mg/1)TabletOralAllergan1996-04-01Not applicableUs0456 045720180913 8702 16rifcr
Armour ThyroidThyroid, porcine (30 mg/1)TabletOralA-S Medication Solutions1996-04-01Not applicableUs
Categories
UNII
0B4FDL9I6P
CAS number
Not Available

Pharmacology

Indication

Replacement or supplemental therapy in hypothyroidism; TSH suppression (in thyroid cancer, nodules, goiters, and enlargement in chronic thyroiditis); diagnostic agent to differentiate suspected hyperthyroidism from euthyroidism.

Pharmacodynamics

Levothyroxine replacement therapy has three main goals. These are (i) to provide resolution of the patients' symptoms and hypothyroid signs, including biological and physiologic markers of hypothyroidism, (ii) to achieve normalization of serum thyrotropin with improvement in thyroid hormone concentrations, and (iii) to avoid overtreatment (iatrogenic thyrotoxicosis), especially in the elderly.

Mechanism of action

It replaces the depleted thyroid hormones in patients with hypothyroidism.

Absorption

Levothyroxine (T 4 ) is only partially absorbed from the GI tract. Absorption varies from 48% to 79%. Fasting increases absorption. Liothyronine (T 3 ) is almost totally absorbed (95%) in 4 h.

Volume of distribution
Not Available
Protein binding

More than 99% is bound to serum proteins.

Metabolism

Deiodination of levothyroxine (T 4 ) occurs at a number of sites, including liver, kidney, and other tissues.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

If any of the following symptoms occurred after overdose administration of thyroid porcine, patient must seek immediate medical attention: Changes in appetite, changes in menstrual periods, chest pain, diarrhea, fast or irregular heartbeat, fever, hand tremors, headache, irritability, leg cramps nervousness, sensitivity to heat, shortness of breath, sweating, trouble sleeping, vomiting, weight loss. In case of overdose toxicity, hypermetabolic state resembling in every respect the condition of endogenous origin.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThyroid, porcine may increase the anticoagulant activities of (R)-warfarin.
(S)-WarfarinThyroid, porcine may increase the anticoagulant activities of (S)-Warfarin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Thyroid, porcine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Thyroid, porcine.
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Thyroid, porcine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Thyroid, porcine.
4-hydroxycoumarinThyroid, porcine may increase the anticoagulant activities of 4-hydroxycoumarin.
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Thyroid, porcine.
7-DeazaguanineThe serum concentration of 7-Deazaguanine can be increased when it is combined with Thyroid, porcine.
7,9-DimethylguanineThe serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Thyroid, porcine.
Food Interactions
Not Available

References

General References
  1. product info [Link]
  2. article [Link]
External Links
PubChem Substance
347910404
AHFS Codes
  • 68:36.04 — Thyroid Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHealthy Volunteers1
Not AvailableRecruitingTreatmentThyroid Papillary Carcinoma1
Not AvailableUnknown StatusTreatmentPrimary Hypothyroidism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral120 mg/1
TabletOral15 mg/1
TabletOral180 mg/1
TabletOral240 mg/1
TabletOral30 mg/1
TabletOral300 mg/1
TabletOral60 mg/1
TabletOral90 mg/1
TabletOral125 mg
TabletOral30 mg
TabletOral60 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on September 16, 2015 15:09 / Updated on March 22, 2019 03:19